Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 11/20 | 0.57 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.41 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.41 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.41 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.41 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.41 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.41 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MYC | P01106 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27185264 | 0.88 | P2RX7 (0.48) | P2RX7AURKATPX2KDM4EHPGD | |
| SCHEMBL15797479 | 0.87 | P2RX7 (0.58) | P2RX7KDM4E | |
| SCHEMBL15797260 | 0.85 | P2RX7 (0.60) | P2RX7AURKATPX2PRKAB2PRKAG1 | |
| SCHEMBL15797422 | 0.84 | P2RX7 (0.56) | P2RX7AURKATPX2KDM4EHPGD | |
| SCHEMBL15797536 | 0.82 | P2RX7 (0.57) | P2RX7AURKATPX2KDM4EHPGD | |
| SCHEMBL18203921 | 0.81 | P2RX7 (0.47) | P2RX7AURKATPX2KDM4EHPGD | |
| SCHEMBL15797734 | 0.81 | P2RX7 (0.61) | P2RX7AURKATPX2PRKAB2PRKAG1 | |
| SCHEMBL15797491 | 0.80 | P2RX7 (0.55) | P2RX7AURKATPX2 | |
| SCHEMBL15821851 | 0.80 | P2RX7 (0.50) | P2RX7AURKATPX2KDM4EHPGD | |
| SCHEMBL15797458 | 0.79 | P2RX7 (0.55) | P2RX7AURKATPX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718774-B2 | Indole carboxamide derivatives as P2X7 receptor antagonist | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-08-01 | — | — | US | claimed |
| US-9556117-B2 | Indole carboxamide derivatives as P2X7 receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2017-01-31 | — | — | US | claimed |
| EP-2931717-B1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-12-07 | — | — | EP | claimed |
| EP-2935211-B1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-11-09 | — | — | EP | claimed |
| US-20150344425-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-03 | — | — | US | claimed |
| US-20150322008-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONIST | ACTELION PHARMACEUTICALS LTD (CH) | 2015-11-12 | — | — | US | claimed |
| EP-2935211-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2015-10-28 | — | — | EP | claimed |
| EP-2931717-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2015-10-21 | — | — | EP | claimed |
| WO-2014097140-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-06-26 | — | — | WO | claimed |
| WO-2014091415-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-06-19 | — | — | WO | claimed |
| EP-3402469-B1 | P2X7 RECEPTOR ANTAGONISTS FOR RESTORING T-CELL LYMPHOPOIESIS IN SUBJECTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) | INST NAT SANTE RECH MED (FR) | 2021-01-06 | — | — | EP | disclosed |
| US-10548980-B2 | P2X7 receptor antagonists for restoring T-cell lymphopoiesis in subjects infected with human immunodeficiency virus (HIV) | INSERM (Institut National de la Santé et de la Recherche Médicale (FR) | 2020-02-04 | — | — | US | disclosed |
| US-20190022223-A1 | P2X7 RECEPTOR ANTAGONISTS FOR RESTORING T-CELL LYMPHOPOIESIS IN SUBJECTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) | INSERM (INSTITUT NATIONAL DE LA SANTÉ ET LA SANTÉ ET DE LA RECHERCHE MÉDICALE) (FR) | 2019-01-24 | — | — | US | disclosed |
| EP-3402469-A1 | P2X7 RECEPTOR ANTAGONISTS FOR RESTORING T-CELL LYMPHOPOIESIS IN SUBJECTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) | Institut National de la Sante et de la Recherche Medicale (INSERM) (FR) | 2018-11-21 | — | — | EP | disclosed |
| US-9718774-B2 | Indole carboxamide derivatives as P2X7 receptor antagonist | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-08-01 | — | — | US | disclosed |
| US-20150322008-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONIST | ACTELION PHARMACEUTICALS LTD (CH) | 2015-11-12 | — | — | US | disclosed |
| EP-2935211-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2015-10-28 | — | — | EP | disclosed |
| EP-2931717-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2015-10-21 | — | — | EP | disclosed |
| WO-2014097140-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014091415-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10548980-B2 | P2X7 receptor antagonists for restoring T-cell lymphopoiesis in subjects infected with human immunodeficiency virus (HIV) | P2RX7, P2RX1, P2RX5 | P2RX7 1/4885AURKA 3535/4885TPX2 138/4885 |
| US-20150344425-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX3, P2RX1 | P2RX7 1/4885AURKA 1211/4885TPX2 984/4885 |
| US-20150322008-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONIST | P2RX3, P2RX7, P2RX1 | P2RX7 2/4885AURKA 1124/4885TPX2 796/4885 |
| US-20190022223-A1 | P2X7 RECEPTOR ANTAGONISTS FOR RESTORING T-CELL LYMPHOPOIESIS IN SUBJECTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) | P2RX7, P2RX1, P2RX5 | P2RX7 1/4885AURKA 3535/4885TPX2 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.